Suppliers / Taenaka Kogyo

Taenaka Kogyo

Japan Updated 9 July 2026

Taenaka Kogyo is an API manufacturer based in Japan. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 12 April 2024 as VAI.

2
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 12 April 2024 VAI US FDA
  • 19 February 2015 NAI US FDA
  • 20 October 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Japan, Japan 3003282619
Mobara-shi, Japan Not on file

What they file, and where

Molecule Regulators Docs
Glutamic Acid EDQM, SFDA (Saudi Arabia), US FDA 3
Cysteine US FDA 1

Also appears on these molecule pages

Glutamic Acid API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Taenaka Kogyo

Does Taenaka Kogyo hold a US DMF or a CEP?
Taenaka Kogyo holds 2 active US drug master files and 1 valid CEP. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Taenaka Kogyo FDA-registered?
One site operated by Taenaka Kogyo carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Taenaka Kogyo's last inspection go?
The most recent inspection on record closed on 12 April 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Taenaka Kogyo manufacture?
2 registered sites are on record, in Japan (Japan and Mobara-shi). Every site is listed on this page with the register it came from.
What does Taenaka Kogyo make?
2 molecules are on record against Taenaka Kogyo, including Glutamic Acid and Cysteine. Each links through to that molecule's full manufacturer list.
Which regulators recognise Taenaka Kogyo's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Checking Taenaka Kogyo?

Ask Fred what the record holds on Taenaka Kogyo, including filings and inspection history.

Chat with Fred, your AI analyst
Opens WhatsApp. Free to start.

Open risk flags

  • The most recent inspection outcome was VAI, on 12 April 2024.

Comparable suppliers

Ajinomoto shares 1 molecule Amino Chemicals shares 1 molecule Mianyang Shengshi Health Technology shares 1 molecule Otsuka Pharmaceutical India shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates